V3-substanceAdminSubstitution.xml

Identifies what sort of change is permitted or has occurred between the therapy that was ordered and the therapy that was/will be provided.

Raw XML

<ValueSet xmlns="http://hl7.org/fhir">
  <text>
    <status value="generated"/>
    <div xmlns="http://www.w3.org/1999/xhtml">
      <p>Release Date: 2014-08-07</p>

      <h2>Description</h2>

      <p>
                  Identifies what sort of change is permitted or has occurred between
           the therapy that was ordered and the therapy that was/will be provided.
        <br/>

               
      </p>

      <hr/>

      <table class="grid">
 
        <tr>
          <td>
            <b>Level</b>
          </td>
          <td>
            <b>Code</b>
          </td>
          <td>
            <b>Display</b>
          </td>
          <td>
            <b>Definition</b>
          </td>
        </tr>
 
        <tr>
          <td>1</td>
          <td>
            <span style="color: grey">
              <i>(_ActSubstanceAdminSubstitutionCode)</i>
            </span>
          </td>
          <td>
            <a name="_ActSubstanceAdminSubstitutionCode"> </a>
          </td>
          <td>
                        
                           Description: Substitution occurred or is permitted with another
               product that may potentially have different ingredients, but having the same biological
               and therapeutic effects.
            <br/>

                     
          </td>
        </tr>
 
        <tr>
          <td>2</td>
          <td>  E
            <a name="E"> </a>
          </td>
          <td>equivalent</td>
          <td>
                        
                           Description: Substitution occurred or is permitted with another
               bioequivalent and therapeutically equivalent product.
            <br/>

                     
          </td>
        </tr>
 
        <tr>
          <td>3</td>
          <td>    EC
            <a name="EC"> </a>
          </td>
          <td>equivalent composition</td>
          <td>
                        
                           Description: 
                        
            <br/>

                        Substitution occurred or is permitted with another product that
               is a:
            <br/>

                        
                           pharmaceutical alternative containing the same active ingredient
               but is formulated with different salt, ester
                           pharmaceutical equivalent that has the same active ingredient,
               strength, dosage form and route of administration
                        
                        
                           Examples: 
                        
            <br/>

                        
                           
                              Pharmaceutical alternative: Erythromycin Ethylsuccinate
               for Erythromycin Stearate
                           
                              Pharmaceutical equivalent: Lisonpril for Zestril
                        
                     
          </td>
        </tr>
 
        <tr>
          <td>4</td>
          <td>      BC
            <a name="BC"> </a>
          </td>
          <td>brand composition</td>
          <td>
                        
                           Description: 
                        
            <br/>

                        Substitution occurred or is permitted between equivalent Brands
               but not Generics
            <br/>

                        
                           Examples: 
                        
            <br/>

                        
                           Zestril  for Prinivil
                           Coumadin for Jantoven
                        
                     
          </td>
        </tr>
 
        <tr>
          <td>4</td>
          <td>      G
            <a name="G"> </a>
          </td>
          <td>generic composition</td>
          <td>
                        
                           Description: Substitution occurred or is permitted between
               equivalent Generics but not Brands
            <br/>

                        
                           Examples: 
                        
            <br/>

                        
                           Lisnopril (Lupin Corp) for Lisnopril (Wockhardt Corp)
                        
                     
          </td>
        </tr>
 
        <tr>
          <td>3</td>
          <td>    TE
            <a name="TE"> </a>
          </td>
          <td>therapeutic alternative</td>
          <td>
                        
                           Description: Substitution occurred or is permitted with another
               product having the same therapeutic objective and safety profile.
            <br/>

                        
                           Examples: 
                        
            <br/>

                        
                           ranitidine for Tagamet
                        
                     
          </td>
        </tr>
 
        <tr>
          <td>4</td>
          <td>      TB
            <a name="TB"> </a>
          </td>
          <td>therapeutic brand</td>
          <td>
                        
                           Description: Substitution occurred or is permitted between
               therapeutically equivalent Brands but not Generics
            <br/>
&gt;
                           Examples: 
                        
            <br/>

                        
                           Zantac for Tagamet
                        
                     
          </td>
        </tr>
 
        <tr>
          <td>4</td>
          <td>      TG
            <a name="TG"> </a>
          </td>
          <td>therapeutic generic</td>
          <td>
                        
                           Description: Substitution occurred or is permitted between
               therapeutically equivalent Generics but not Brands
            <br/>
&gt;
                           Examples: 
                        
            <br/>

                        
                           Ranitidine  for cimetidine
                        
                     
          </td>
        </tr>
 
        <tr>
          <td>2</td>
          <td>  F
            <a name="F"> </a>
          </td>
          <td>formulary</td>
          <td>
                        
                           Description: This substitution was performed or is permitted
               based on formulary guidelines. 
            <br/>

                     
          </td>
        </tr>
 
        <tr>
          <td>2</td>
          <td>  N
            <a name="N"> </a>
          </td>
          <td>none</td>
          <td>
                        No substitution occurred or is permitted.
            <br/>

                     
          </td>
        </tr>

      </table>

    </div>
  </text>
  <identifier value="http://hl7.org/fhir/v3/vs/substanceAdminSubstitution"/>
  <name value="v3 Code System substanceAdminSubstitution"/>
  <publisher value="HL7, Inc"/>
  <telecom>
    <system value="url"/>
    <value value="http://hl7.org"/>
  </telecom>
  <description value=" Identifies what sort of change is permitted or has occurred between the therapy that
     was ordered and the therapy that was/will be provided."/>
  <status value="active"/>
  <date value="2014-08-07T00:00:00+10:00"/>
  <define>
    <system value="http://hl7.org/fhir/v3/substanceAdminSubstitution"/>
    <caseSensitive value="true"/>
    <concept>
      <code value="_ActSubstanceAdminSubstitutionCode"/>
      <abstract value="true"/>
      <display value="ActSubstanceAdminSubstitutionCode"/>
      <definition value="Description: Substitution occurred or is permitted with another product that may potentially
         have different ingredients, but having the same biological and therapeutic effects."/>
      <concept>
        <code value="E"/>
        <display value="equivalent"/>
        <definition value="Description: Substitution occurred or is permitted with another bioequivalent and therapeutically
           equivalent product."/>
        <concept>
          <code value="EC"/>
          <display value="equivalent composition"/>
          <definition value="Description:                                                    Substitution occurred
             or is permitted with another product that is a:                                      
                            pharmaceutical alternative containing the same active ingredient but is
             formulated with different salt, ester                            pharmaceutical equivalent
             that has the same active ingredient, strength, dosage form and route of administration
                                                                                          Examples:
                                                                                                  
                                     Pharmaceutical alternative: Erythromycin Ethylsuccinate for Erythromycin
             Stearate                                                           Pharmaceutical equivalent:
             Lisonpril for Zestril"/>
          <concept>
            <code value="BC"/>
            <display value="brand composition"/>
            <definition value="Description:                                                    Substitution occurred
               or is permitted between equivalent Brands but not Generics                           
                                         Examples:                                                  
                                            Zestril  for Prinivil                            Coumadin
               for Jantoven"/>
          </concept>
          <concept>
            <code value="G"/>
            <display value="generic composition"/>
            <definition value="Description: Substitution occurred or is permitted between equivalent Generics but not
               Brands                                                      Examples:                
                                                                              Lisnopril (Lupin Corp)
               for Lisnopril (Wockhardt Corp)"/>
          </concept>
        </concept>
        <concept>
          <code value="TE"/>
          <display value="therapeutic alternative"/>
          <definition value="Description: Substitution occurred or is permitted with another product having the same
             therapeutic objective and safety profile.                                            
                      Examples:                                                                   
                         ranitidine for Tagamet"/>
          <concept>
            <code value="TB"/>
            <display value="therapeutic brand"/>
            <definition value="Description: Substitution occurred or is permitted between therapeutically equivalent
               Brands but not Generics &gt;                            Examples:                    
                                                                          Zantac for Tagamet"/>
          </concept>
          <concept>
            <code value="TG"/>
            <display value="therapeutic generic"/>
            <definition value="Description: Substitution occurred or is permitted between therapeutically equivalent
               Generics but not Brands &gt;                            Examples:                    
                                                                          Ranitidine  for cimetidine"/>
          </concept>
        </concept>
      </concept>
      <concept>
        <code value="F"/>
        <display value="formulary"/>
        <definition value="Description: This substitution was performed or is permitted based on formulary guidelines."/>
      </concept>
      <concept>
        <code value="N"/>
        <display value="none"/>
        <definition value="No substitution occurred or is permitted."/>
      </concept>
    </concept>
  </define>
</ValueSet>